Table 2.
Comparative analysis of clinical trial outcomes for RRMM.
| Treatment regimens | Study | Number of patients enrolled | Median number of lines of therapy | Median follow-up time (months) | Objective response rate (%) | CR rate (%) | MRD negativity rate (%) | Median time to response (months) | Median PFS (months) |
|---|---|---|---|---|---|---|---|---|---|
| Sd | STORM[44] | 122 | 7 | 8.3 | 26 | 2 | NA | 1 | 3.7 |
| DPd | EQUULEUS/MMY1001[36] | 103 | 4 | 13.1 | 60 | 17 | NA | 1 | 8.8 |
| EPD | ELOQUENT-3[38] | 60 | 3 | 9.1 | 53 | 8 | NA | 2 | 10.3 |
| IsaPd | ICARIA-MM[35] | 154 | 3 | 11.6 | 60 | 5 | NA | 1 | 11.5 |
| DKd | CANDOR[33] | 312 | 2 | 16.9 | 84.3 | 29 | NA | 1 | 28.6 |
| DVd | CASTOR[51] | 251 | 2 | 19.4 | 83.8 | 28.8 | 11.6 | – | 16.7 |
| PVd | OPTIMISMM[52] | 281 | 2 | 15.9 | 82.2 | 15.7 | NA | 0.9 | 11.2 |
CR: Complete response; DKd: Daratumumab combined with carfilzomib and dexamethasone; DPd: Daratumumab combined with pomalidomide and dexamethasone; DVd: Daratumumab combined with bortezomib and dexamethasone; EPd: Elotuzumab combined with pomalidomide and dexamethasone; IsaPd: Isatuximab combined with pomalidomide and dexamethasone; NA: Not available; MM: Multiple myeloma; MRD: Minimal residual disease; PFS: Progression-free survival; Pvd: Pomalidomide combined with bortezomib and dexamethasone; RRMM: relapsed/refractory MM; Sd: Selinexor combined with dexamethasone; Vd: Bortezomib combined with dexamethasone.